Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Asaf Zviran
|
| gptkbp:collaboratesWith |
gptkb:Mayo_Clinic
National Cancer Center Singapore |
| gptkbp:focus |
cancer diagnostics
|
| gptkbp:foundedIn |
2019
|
| gptkbp:founder |
gptkb:Erez_Lieberman_Aiden
Asaf Zviran Ophir Shalem |
| gptkbp:fundedBy |
gptkb:Series_A
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
C2i Genomics
|
| gptkbp:industry |
gptkb:biotechnology
healthcare |
| gptkbp:investor |
gptkb:Casdin_Capital
gptkb:NFX The Mark Foundation for Cancer Research |
| gptkbp:mission |
improving cancer treatment monitoring
|
| gptkbp:product |
C2-Intelligence Platform
|
| gptkbp:specializesIn |
minimal residual disease detection
|
| gptkbp:technology |
liquid biopsy
AI-driven cancer monitoring |
| gptkbp:website |
https://www.c2i-genomics.com/
|
| gptkbp:bfsParent |
gptkb:Hanaco_Venture_Capital
gptkb:Stanley_Lapidus |
| gptkbp:bfsLayer |
7
|